Experimental Medicine Training Initiative Clinical Research Associate/Clinical PhD
Applications now open
As part of the Experimental Medicine Training Initiative, this is a prestigious fully-funded, Clinical PhD Studentship at the University of Cambridge. This innovative initiative is a partnership between the University of Cambridge, Cambridge Biomedical Research Centre and Pharmaceutical Companies. The Studentship is available from April 2018, and provides an unrivalled opportunity to undertake high quality clinical research in the area of nephrology and clinical pharmacology, in collaboration with AstraZeneca. It will appeal to clinical trainees from a wide range of disciplines including Clinical Pharmacology, Nephrology and Acute Medicine. The Studentship award will cover a clinical stipend for 3 years, University and College fees, and a generous training allowance. This project is a unique opportunity to join a collaboration between the Division of Experimental Medicine and Immunotherapeutics at the University of Cambridge, and the Renal division at AstraZeneca.
Project: Novel Approaches to the Emergency Management of Hyperkalaemia
The remit will be to study the epidemiology, sequelae and treatment of hyperkalaemia with particular reference to the emergency setting. Existing treatments have important limitations. Novel treatment options exist and the studentship will be focused on the design and conduct of epidemiological, physiological and proof of concept studies to develop novel approaches to the emergency management of hyperkalaemia. Working closely with leading investigators in the Division of Experimental Medicine and Immunotherapeutics from the University of Cambridge, the Cambridge Clinical Trials Unit and AstraZeneca, you will apply the findings of these studies to the design of a late phase emergency medicine trial.
This project will provide you with an opportunity to apply your strengths to emergency, renal and experimental medicine, and will provide a unique hands-on perspective of translational medicine. The successful applicant will be offered the opportunity to spend time with AstraZeneca and international academic collaborators. The structured mentoring and training environment will allow the candidate to develop as an academic clinician with expertise in designing and conducting experimental medicine studies and later phase trials.
It is essential that the applicant is fully registered with the GMC, and desirable that they already hold a National Training Number. They must successfully complete an application to the Department of Medicine PhD course, at the University of Cambridge.
For general queries on the Experimental Medicine Training Initiative please contact Professor Ian Wilkinson (Director of the EMI), on 01223 336 806; interested candidates are encouraged to contact Dr Thomas Hiemstra (01223 336 817 or via email firstname.lastname@example.org) for informal enquiries.
Please quote reference RC14549 on your application and in any correspondence about this vacancy.
Apply- by going to the University jobs pages – http://www.jobs.cam.ac.uk/job/16372/
Click on the ‘apply online’ button at the bottom of the page.
Close date: extended to 04 March 2018
Interviews: w/c 12 March 2018
It is essential that the applicant is fully registered with the GMC and medically qualified and desirable that they already hold a National Training Number.
For general queries on the Experimental Medicine Training Initiative please contact Professor Ian Wilkinson (Director of the EMI), on 01223 336 806.
There are two stages of application and approval:
- Application and interview by a panel of University and industry academics.
- The successful applicant will then apply to the University of Cambridge PhD course and be subject to the graduate admissions process of the University of Cambridge.
The University values diversity, is committed to equality of opportunity, and has a responsibility to ensure that all employees are eligible to live and work in the UK.